Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection

Pan,Tao; Liu,Xiaoyun; Xiang,Shougui; Ji,Wenli

doi:10.3892/etm.2016.3051

Treatment for patients with multidrug resistant Acinetobacter baumannii pulmonary infection

Authors:
- Tao Pan
- Xiaoyun Liu
- Shougui Xiang
- Wenli Ji
View Affiliations

Affiliations: Department of Intensive Care Medicine, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei 441000, P.R. China
Published online on: February 8, 2016 https://doi.org/10.3892/etm.2016.3051
Pages: 1345-1347
Copyright: © Pan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bacterial infections are common but have become increasingly resistant to drugs. The aim of the present study was to examine the combined treatment of traditional Chinese and Western medicine in 30 cases of pulmonary infection with multidrug resistant Acinetobacter baumannii. Patients were divided into groups A and B according to drug treatments. Cefoperazone or sulbactam and tanreqing were administered in group A, and cefoperazone or sulbactam in group B. The curative effect and prognosis of the two groups were recorded and the remaining treatments were performed routinely in the clinic. For the combined therapy group, which was administered sulperazone and tanreqing, 8 patients were recovered, 6 patients had significant effects, 3 patients exhibited some improvement and 1 patient had no response. One of the patients did not survive after 28 days. By contrast, there were 4 patients that were successfully treated, 3 patients with significant effects, 2 patients with some improvement and 2 patients had no response in the sulperazone group, and 4 patients did not survive after 28 days. In conclusion, the combined therapy of cefoperazone or sulbactam supplemented with tanreqing was identified to be more effective than cefoperazone or sulbactam as monotherapy, for treating multidrug resistant Acinetobacter baumannii.

View Figures

View References

1	El-Ageery SM and Al-Hazmi SS: Microbiological and molecular detection of VIM-1 metallo beta lactamase-producing Acinetobacter baumannii. Eur Rev Med Pharmacol Sci. 18:965–970. 2014.PubMed/NCBI
2	El-Ageery SM, Abo-Shadi MA, Alghaithy AA, Ahmad MA, Alsharif NH and Alharbi SA: Epidemiological investigation of nosocomial infection with multidrug-resistant Acinetobacter baumannii. Eur Rev Med Pharmacol Sci. 16:1834–1839. 2012.PubMed/NCBI
3	López-Rojas R, Docobo-Pérez F, Pachón-Ibáñez ME, de la Torre BG, Fernández-Reyes M, March C, Bengoechea JA, Andreu D, Rivas L and Pachón J: Efficacy of cecropin A-melittin peptides on a sepsis model of infection by pan-resistant Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 30:1391–1398. 2011. View Article : Google Scholar : PubMed/NCBI
4	Shao BB and Feng HB: Successful treatment of pan-resistant Acinetobacter baumannii infection of the lung with tigecycline: a report of one case. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 25:6362013.(In Chinese). PubMed/NCBI
5	Magiorakos AP, Srinvasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT and Monnet DL: Multidrug resistant extensively drug Resistant and paddrug-resistant bacteria: an international expert proptsal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 18:268–281. 2012. View Article : Google Scholar : PubMed/NCBI
6	Doi Y, Onuoha EO, Adams-Haduch JM, Pakstis DL, McGaha TL, Werner CA, Parker BN, Brooks MM, Shutt KA, Pasculle AW, et al: Screening for Acinetobacter baumannii colonization by use of sponges. J Clin Microbiol. 49:154–158. 2011. View Article : Google Scholar : PubMed/NCBI
7	Spellberg B and Talbot G: Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 51(Suppl 1): S150–S170, D. 2010. View Article : Google Scholar : PubMed/NCBI
8	Tekçe AY, Erbay A, Çabadak H, Yağcı S, Karabiber N and Şen S: Pan-resistant Acinetobacter baumannii mediastinitis treated successfully with tigecycline: a case report. Surg Infect (Larchmt). 12:141–143. 2011. View Article : Google Scholar : PubMed/NCBI
9	Antunes LC, Imperi F, Minandri F and Visca P: In vitro and in vivo antimicrobial activities of gallium nitrate against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 56:5961–5970. 2012. View Article : Google Scholar : PubMed/NCBI
10	Telang NV, Satpute MG, Dhakephalkar PK, Niphadkar KB and Joshi SG: Fulminating septicemia due to persistent pan-resistant community-acquired metallo-β-lactamase (IMP-1)-positive Acinetobacter baumannii. Indian J Pathol Microbiol. 54:180–182. 2011. View Article : Google Scholar : PubMed/NCBI
11	Vila-Farres X, de la Maria Garcia C, López-Rojas R, Pachón J, Giralt E and Vila J: In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin Microbiol Infect. 18:383–387. 2012. View Article : Google Scholar : PubMed/NCBI
12	Prata-Rocha ML, Gontijo-Filho PP and Melo GB: Factors influencing survival in patients with multidrug-resistant Acinetobacter baumannii infection. Braz J Infect Dis. 16:237–241. 2012. View Article : Google Scholar : PubMed/NCBI
13	McConnell MJ, Rumbo C, Bou G and Pachón J: Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine. 29:5705–5710. 2011. View Article : Google Scholar : PubMed/NCBI
14	Le Hello S, Falcot V, Lacassin F, Mikulski M and Baumann F: Risk factors for carbapenem-resistant Acinetobacter baumannii infections at a tertiary care hospital in New Caledonia, South Pacific. Scand J Infect Dis. 42:821–826. 2010. View Article : Google Scholar : PubMed/NCBI
15	Sun SM, Wang YY, Yao CJ, Li HL, Yu F, Zhang YL, Zhou H and Wang NP: Clinical characteristics and therapy of pan-drug resistant Acinetobacter baumannii infection. Nan Fang Yi Ke Da Xue Xue Bao. 30:2351–2353, 2359. 2010.(In Chinese). PubMed/NCBI
16	Principe L, D'Arezzo S, Capone A, Petrosillo N and Visca P: In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob. 8:182009. View Article : Google Scholar : PubMed/NCBI
17	Lü Y, Li Y, Xue F, Zhang XZ, Hu YJ, Jin YF, Chu YZ, Hu ZD, Zhao JH, Pan SY, et al: Analysis of resistance tendency of bloodstream-infecting pathogens in China. Zhonghua Jie He He Hu Xi Za Zhi. 36:411–419. 2013.(In Chinese). PubMed/NCBI
18	Taccone FS, Rodriguez-Villalobos H, De Backer D, De Moor V, Deviere J, Vincent JL and Jacobs F: Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis. 25:257–260. 2006. View Article : Google Scholar : PubMed/NCBI
19	Navon-Venezia S, Ben-Ami R and Carmeli Y: Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis. 18:306–313. 2005. View Article : Google Scholar : PubMed/NCBI
20	Ozdem B, Gürelik FC, Celikbilek N, Balıkçı H and Açıkgöz ZC: Antibiotic resistance profiles of Acinetobacter species isolated from several clinical samples between 2007–2010. Mikrobiyol Bul. 45:526–534. 2011.(In Turkish). PubMed/NCBI
21	Kulkova N, Babalova M, Sokolova J and Krcmery V: First report of New Delhi metallo-β-lactamase-1-producing strains in Slovakia. Microb Drug Resist. 21:117–120. 2015. View Article : Google Scholar : PubMed/NCBI
22	Fica CA, Céspedes JI, Gompertz GM, Jalón VM, Sakurada ZA and Sáez LE: Intravenous colistin in the treatment of infections due to pan-resistant Gram negative bacilli. Rev Chilena Infectol. 24:360–367. 2007.(In Spanish). PubMed/NCBI
23	Marimuthu K, Gunaselvam P, Rahman Aminur M, Xavier R, Arockiaraj J, Subramanian S, Yusoff FM and Arshad A: Antibacterial activity of ovary extract from sea urchin Diadema setosum. Eur Rev Med Pharmacol Sci. 19:1895–1899. 2015.PubMed/NCBI
24	Karakoc C, Tekin R, Yeşilbağ Z and Cagatay A: Risk factors for mortality in patients with nosocomial Gram-negative rod bacteremia. Eur Rev Med Pharmacol Sci. 17:951–957. 2013.PubMed/NCBI
25	Gao Z, Xing H, Sun H and Li H: Experiment study on the pathogenicity of Staphylococcus aureus in laboratory mice. Chin J Comp Med. 13:87–89. 2003.